35856-61-2

Usage

Uses

Used in Pharmaceutical Synthesis:
Sulfamoyl chloride, ethyl(methyl)is utilized as a key intermediate in the production of pharmaceuticals. Its role is crucial for the synthesis of various drug molecules, where it aids in the formation of sulfonamide derivatives, contributing to the development of new medications with potential therapeutic applications.
Used in Agrochemical Production:
In the agrochemical industry, sulfamoyl chloride, ethyl(methyl)serves as an intermediate for the synthesis of compounds used in crop protection and pest control. Its ability to form sulfamoyl derivatives is leveraged to create active ingredients in herbicides, insecticides, and fungicides, enhancing agricultural productivity and crop protection.
Used in Specialty Chemicals:
Sulfamoyl chloride, ethyl(methyl)is also employed in the creation of specialty chemicals, which are often used in specific applications due to their unique properties. sulfamoyl chloride, ethyl(methyl)contributes to the development of these chemicals by facilitating the introduction of the sulfamoyl group, which can impart specific functionalities to the final products.
Used in Organic Synthesis as a Reagent:
As a reagent in organic synthesis, sulfamoyl chloride, ethyl(methyl)is applied for introducing the sulfamoyl group into a variety of organic molecules. Its reactivity with nucleophiles allows for the formation of sulfamoyl derivatives, which can be further utilized in the synthesis of complex organic compounds for various applications across different industries.

Upstream product

• 624-78-2 N-Ethylmethylamine 

Relevant academic research and scientific papers

POLYCYCLIC COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES

The present disclosure relates to bifunctional compounds, ULM— L—PTM, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A- RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.

ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF

Disclosed herein are methods and compounds of augmenting and enhancing the production of type I IFNs in vivo. In some embodiments, the compounds disclosed herein are ENPP-1 inhibitors, pharmaceutical compositions, and methods for the treatment of cancer or a viral infection.

PYRIMIDINYL-PYRIDYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF TREATING IRE1-RELATED DISEASES AND DISORDERS

Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula (I) or (I') structure : or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula (I) or (I') compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Compounds for kinase modulation, and indications therefor

Compounds active on protein kinases and methods for regulating protein kinase pathways are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.